Risk free rate

Pembrolizumab achieves pre-specified event-free survival in high-risk TNBCs

Patients with high-risk, early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488) with pembrolizumab (Keytruda) plus chemotherapy after surgery demonstrated event-free survival ( SSE) statistically significant, according to a press release from Merck.1 Compared with preoperative chemotherapy, an interim Data Monitoring Committee analysis revealed that neoadjuvant pembrolizumab …

Read More »

Pembrolizumab clinical trial shows improvement in event-free survival in high-risk, early-stage triple-negative breast cancer

The KEYNOTE-522 trial met its two primary endpoints of complete pathologic response and event-free survival, showing statistically significant and clinically significant improvement in SES compared to neoadjuvant chemotherapy alone. A pivotal study of pembrolizumab (Keytruda, Merck) in combination with chemotherapy showed statistically significant improvements in event-free survival (ESS) in patients …

Read More »